Summary
Clinical characteristics.
SETBP1 haploinsufficiency disorder (SETBP1-HD) is characterized by hypotonia and mild motor developmental delay; intellectual abilities ranging from normal to severe disability; speech and language disorder; behavioral problems (most commonly attention/concentration deficits and hyperactivity, impulsivity), and refractive errors and strabismus. Typically children with SETBP1-HD whose intellect is in the normal or borderline range (IQ 80-90) were diagnosed following genetic testing for behavioral problems and/or severe speech and language disorders (respectively: the inability to produce sounds in words correctly, and deficits in the understanding and/or expression of words and sentences). To date, 47 individuals with SETBP1-HD have been reported.
Diagnosis/testing.
The diagnosis of SETBP1-HD is established in a proband with suggestive findings and a heterozygous pathogenic loss-of-function variant in SETBP1 identified by molecular genetic testing.
Management.
Treatment of manifestations: Treatment is supportive, often including multidisciplinary specialists from pediatrics, neurology, physiatry, occupational and physical therapy, speech-language pathology, psychiatry, ophthalmology, and medical genetics. Early intervention programs and special education programs may be needed to address developmental disabilities.
Surveillance: Monitoring of: feeding and weight gain; developmental/educational progress and needs; speech and language progress and needs; psychiatric and behavioral interventions; ophthalmologic interventions.
Genetic counseling.
SETBP1-HD is an autosomal dominant disorder typically caused by a de novo pathogenic variant. Most probands reported to date whose parents have undergone molecular genetic testing have the disorder as the result of a de novo SETBP1 pathogenic variant. Rarely, individuals with SETBP1-HD may have the disorder as the result of a SETBP1 pathogenic variant inherited from a parent with germline (or somatic and germline) mosaicism. Once the SETBP1 pathogenic variant has been identified in an affected family member, prenatal and preimplantation genetic testing are possible.
Diagnosis
No consensus clinical diagnostic criteria for SETBP1 haploinsufficiency disorder have been published.
Suggestive Findings
SETBP1 haploinsufficiency disorder (SETBP1-HD) should be considered in individuals with the following clinical findings.
Clinical findings present in most individuals
- Motor developmental delay (in 97%)
- Developmental delay / mild-to-severe intellectual disability
- Learning difficulties
- Speech and language disorder (including childhood apraxia of speech)
Variable findings in infants or children
- Generalized hypotonia of infancy
- Feeding difficulties
- Seizures/epilepsy
- Behavior consistent with attention-deficit/hyperactivity disorder including impulsivity
- Other behaviors such as anxiety, aggression, sleep disturbances, self-injury and/or autism spectrum disorder
- Ophthalmologic findings: refractive errors (hypermetropia, myopia, astigmatism), strabismus)
- Digestive problems
- Subtle dysmorphic features in several individuals: ptosis, blepharophimosis, broad nasal bridge, hypertelorism, full nasal tip, and a high arched palate. See Figure 1 and Jansen et al [2021].
Family history. Because SETBP1 haploinsufficiency disorder is typically caused by a de novo pathogenic variant, most probands represent a simplex case (i.e., a single occurrence in a family). Rarely, a proband may have an affected sib or a parent with mild findings suggestive of SETBP1 haploinsufficiency disorder.
Establishing the Diagnosis
The diagnosis of SETBP1 haploinsufficiency disorder is established in a proband with suggestive findings and a heterozygous pathogenic (or likely pathogenic) loss-of-function variant in SETBP1 identified by molecular genetic testing (see Table 1).
Note: (1) Per ACMG/AMP variant interpretation guidelines, the terms "pathogenic variant" and "likely pathogenic variant" are synonymous in a clinical setting, meaning that both are considered diagnostic and can be used for clinical decision making [Richards et al 2015]. Reference to "pathogenic variants" in this GeneReview is understood to include any likely pathogenic variants. (2) Identification of a heterozygous SETBP1 variant of uncertain significance does not itself establish or rule out the diagnosis.
Molecular genetic testing in a child with developmental delay or an older individual with intellectual disability may begin with chromosomal microarray analysis (CMA). Other options include use of a multigene panel or comprehensive genomic testing. Note: Single-gene testing (sequence analysis of SETBP1, followed by gene-targeted deletion/duplication analysis) is rarely useful and typically NOT recommended.
- An intellectual disability (ID) multigene panel that includes SETBP1 and other genes of interest (see Differential Diagnosis) limits identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. Of note, given the rarity of SETBP1 haploinsufficiency disorder, some panels for intellectual disability may not include this gene. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.
- Comprehensive genomic testing does not require the clinician to determine which gene(s) are likely involved. Exome sequencing is most commonly used and yields results similar to an ID multigene panel – with the additional advantage that exome sequencing includes genes recently identified as causing ID, whereas some multigene panels may not.Genome sequencing is also possible.
Clinical Characteristics
Clinical Description
The most common clinical manifestations of SETBP1 haploinsufficiency disorder (SETBP1-HD) are mild motor developmental delay and hypotonia, speech and language disorder, intellectual disability, attention-deficit/hyperactivity disorder (ADHD), and refractive errors and strabismus.
To date, 47 individuals with SETBP1-HD have been reported [Leonardi et al 2020, Jansen et al 2021, Morgan et al 2021]. The following description of the phenotypic features associated with this condition is based on these reports (Table 2).
Delayed Motor Milestones
Gross motor abilities are generally better than fine motor abilities [Jansen et al 2021, Morgan et al 2021]. Ninety-four per cent had generalized motor delay or disorder [Morgan et al 2021]. Hypotonia may be noted in infancy and is commonly observed during childhood.
Sitting, crawling, and walking are delayed. Average age of sitting unsupported is six to 15 months, crawling nine to 19 months, and walking 13 to 36 months.
Fine motor development is delayed in about 70% of affected children. In particular, some children have difficulty with handwriting, which can further affect development of written language and/or exacerbate literacy difficulties [Morgan et al 2021].
Speech and Language Disorder
The terms speech disorder and language disorder are often used interchangeably. Although they often co-occur, each can occur independently, providing evidence that they are separate entities.
Speech involves producing sounds in words with the correct breath support, voicing, resonance, articulation, prosody, and accuracy. Language involves meaning, i.e., the understanding and expression of words (vocabulary) and sentences (grammar).
Speech disorders and language disorders can each be further classified clinically.
Speech disorders. The five most common speech disorder diagnoses are included in Table 3. Children with SETBP1-HD present with speech delay (first words by 18 months in 50%) due to a severe childhood apraxia of speech (seen in 80%) [Morgan et al 2021]. With speech therapy (see Management), childhood apraxia of speech resolves, and dysarthria becomes more evident.
Children with SETBP1-HD also have phonologic disorder which places them at risk for longer-term literacy difficulties (i.e., disorders of spelling and reading).
Due to the childhood apraxia of speech, some children remain minimally verbal for years and augment their speech and language with sign language, gestures, or augmentative and assistive communication devices [Morgan et al 2021]. (See Management.)
Language disorders. Children with SETBP1-HD have a mild-to-moderate expressive and receptive language disorder (Table 4). In about 30% of affected individuals, receptive language may be better than expressive language [Morgan et al 2021].
Children are typically sociable with a strong desire to communicate, yet social language is poorer than for typically developing peers.
Intellectual Disability (ID)
The spectrum of intellectual disability (noted in 80% of individuals) ranges from mild to severe.
Children with SETBP1-HD whose intellect is in the normal or borderline range (IQ 80-90) typically were diagnosed following genetic testing for severe speech and language disorder and/or behavioral problems.
Behavioral Problems
Most commonly reported are attention/concentration deficits and hyperactivity, and impulsivity, leading in many instances to a diagnosis of ADHD. Other behavioral problems include anxiety, autism spectrum disorder (ASD), sleep disturbances, self-injury, and other aggressive behaviors. Some children have autism or autistic features and social communication disorders. While many children with SETBP1-HD are not diagnosed with ASD, many have restricted interests and sensory sensitivities that overlap with an ASD phenotype.
Additional Findings
Ophthalmologic involvement includes refractive errors, most commonly hypermetropia, and less commonly astigmatism and myopia. Strabismus is also seen.
Feeding difficulties. Poor sucking and slow feeding related to hypotonia can be evident in the neonatal period and infancy. Some children require nasogastric tube feeding. Beyond infancy and into the preschool years, some children experience problems chewing lumpy or solid foods.
Excessive drooling. Some young children have difficulty managing saliva, resulting in excessive drooling that may in turn lead to skin irritation.
Ankyloglossia (i.e., a short frenulum) is more common than in the healthy population (prevalence is 3%-5%). While a short frenulum is not related to delays in speech development, it can affect articulation and pronunciation. A short frenulum may contribute to feeding difficulties.
Cryptorchidism is noted in about 20% of males, although to date SETP1-HD has not been associated with other urogenital abnormalities.
Digestive problems include diarrhea, constipation, food allergies, reflux, and GERD.
Seizures/epilepsy. The majority of seizures (reported in ~20% of individuals) were infantile febrile seizures.
Epilepsy was reported in three individuals, all of whom had generalized seizures [Coe et al 2014, Leonardi et al 2020]. In two of three, onset was in infancy; in the third onset was at age 22 years. After epileptic seizures ceased in one child at age six years, anti-seizure medication was successfully discontinued.
Skeletal abnormalities observed in 14 individuals include bilateral hip dysplasia, abnormal vertebrae at birth, hyperkyphosis, hyperlordosis, increased lumbar lordosis, and (in 10 of the 14 individuals) slight abnormalities of the extremities including bilateral fifth finger clinodactyly, slight 2-3 syndactyly, brachydactyly, and pes cavus [Jansen et al 2021].
Subtle dysmorphic features in several individuals include ptosis, blepharophimosis, broad nasal bridge, hypertelorism, full nasal tip, and a high arched palate. See Figure 1 and Jansen et al [2021].
Other
The following were normal:
- Growth parameters in general (e.g., weight, height, head circumference)
- MRI findings in 19 of 22 individuals (for whom data were available). Of the remaining three, two had delayed myelination and one had a thin corpus callosum and a rotated hippocampal tail [Leonardi et al 2020, Jansen et al 2021].
The possible relationship of the following findings to SETBP1-HD is unknown, given the high frequency of these findings in the general population:
- Recurrent ear infections (~25% of infants)
- Dry skin and/or eczema (20% of individuals)
- Different types of hearing impairment (3 individuals)
Prognosis
Based on current data, life span is not shortened in SETBP1-HD, as several adults have been reported. To date, data are limited on possible progression of behavioral abnormalities and/or neurologic findings.
Genotype-Phenotype Correlations
SETBP1 loss-of-function variants have no genotype-phenotype correlations.
Prevalence
To date, 47 individuals with SETBP1-HD have been reported in the medical literature. (While additional information about SETBP1 variants observed in affected individuals has been reported in genetic databases and/or the literature, this information is not included in this chapter due to absent or limited clinical information.)
The prevalence of SETBP1-HD is unknown.
Genetically Related (Allelic) Disorders
Schinzel-Giedion syndrome. Germline gain-of-function pathogenic variants in SETBP1 are known to be associated with Schinzel-Giedion syndrome, a severe multi-system disorder characterized by recognizable facial characteristics, severe-profound intellectual disability, intractable epilepsy, cortical visual impairment, deafness, and congenital anomalies such as cardiac defects, urogenital defects, and bone abnormalities. Causative pathogenic variants are clustered within a 12-base-pair hot spot region in exon 4.
Sporadic tumors (including myelodysplastic/myeloproliferative neoplasms, atypical chronic myeloid leukemia, chronic myelomonocytic leukemia, and juvenile myelomonocytic leukemia as well as in secondary acute myeloid leukemia) may contain a somatic gain-of-function variant in SETBP1 that is not present in the germline [Makishima 2017]. In these circumstances predisposition to these tumors is not heritable. For more information, see Cancer and Benign Tumors.
Differential Diagnosis
Because the phenotypic features associated with SETBP1 haploinsufficiency disorder overlap with many genetic conditions, all disorders with intellectual disability and severe speech disorder without other distinctive findings should be considered in the differential diagnosis. See OMIM Autosomal Dominant, Autosomal Recessive, Nonsyndromic X-Linked, and Syndromic X-Linked Intellectual Developmental Disorder Phenotypic Series.
Management
No clinical practice guidelines for SETBP1 haploinsufficiency disorder (SETBP1-HD) have been published. Management recommendations below are based on information in the current literature and the Authors' clinical experience.
Evaluations Following Initial Diagnosis
To establish the extent of disease and needs in an individual diagnosed with SETBP1 haploinsufficiency disorder, the evaluations summarized in Table 5 (if not performed as part of the evaluation that led to diagnosis) are recommended.
Treatment of Manifestations
Treatment is supportive, often including multidisciplinary specialists from pediatrics, neurology, physiatry, occupational and physical therapy, speech-language pathology, psychiatry, ophthalmology, and medical genetics.
Developmental Delay / Intellectual Disability Management Issues
The following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country.
Ages 0-3 years. Referral to an early intervention program is recommended for access to occupational, physical, speech-language, and feeding therapy as well as infant mental health services, special educators, and sensory impairment specialists. In the US, early intervention is a federally funded program available in all states that provides in-home services to target individual therapy needs.
Ages 3-5 years. In the US, developmental preschool through the local public school district is recommended and results from referral to Child Find programs. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed for those who qualify based on established motor, language, social, or cognitive delay. The early intervention program typically assists with this transition. Developmental preschool is center based; for children too medically unstable to attend, home-based services are provided.
All ages. Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies (US) and to support parents in maximizing quality of life. Some issues to consider:
- IEP services:
- An IEP provides specially designed instruction and related services to children who qualify.
- IEP services will be reviewed annually to determine whether any changes are needed.
- Special education law requires that children participating in an IEP be in the least restrictive environment feasible at school and included in general education as much as possible, when and where appropriate.
- Vision and hearing consultants should be a part of the child's IEP team to support access to academic material.
- PT, OT, and speech services will be provided in the IEP to the extent that the need affects the child's access to academic material. Beyond that, private supportive therapies based on the affected individual's needs may be considered. Specific recommendations regarding type of therapy can be made by a developmental pediatrician.
- As a child enters the teen years, a transition plan should be discussed and incorporated in the IEP. For those receiving IEP services, the public school district is required to provide services until age 21.
- Vocational opportunities and programming including vocational rehabilitation should be considered early with a focus on achievement of meaningful employment
- A 504 plan (Section 504: a US federal statute that prohibits discrimination based on disability) can be considered for those who require accommodations or modifications such as front-of-class seating, assistive technology devices, classroom scribes, extra time between classes, modified assignments, and enlarged text.
- Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a US public agency that provides services and support to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.
- Families with limited income and resources may also qualify for supplemental security income (SSI) for their child with a disability.
Motor Dysfunction
Fine motor dysfunction. Occupational therapy is recommended for difficulty with fine motor skills that affect adaptive function such as self-feeding, grooming, dressing, and writing.
Oral motor dysfunction. Feeding therapy (typically from a speech-language pathologist or occupational therapist) is recommended to help improve coordination of oral movement skills for feeding or sensory-related feeding issues using relevant approaches including postural modification and altering the consistency of food and fluid [Morgan et al 2012]. Mothers may need support from a breastfeeding or lactation consultant in the early weeks or months of life.
Gross motor dysfunction. Physical therapy may be recommended for difficulty with crawling, walking, running, and building strength resulting from hypotonia.
Speech and language disorder. Consider evaluation for nonverbal support or alternative means of communication (e.g., augmentative and alternative communication [AAC]) for individuals with severe speech and expressive language difficulties. An AAC evaluation can be completed by a speech-language pathologist who has expertise in the area. The evaluation will consider cognitive abilities and sensory impairments to determine the most appropriate form of communication.
AAC devices can range from low-tech, such as picture exchange communication, to high-tech, such as voice-generating devices. Contrary to popular belief, AAC devices do not hinder verbal development of speech, but rather support optimal speech and language development.
In terms of verbal development, difficulties with motor planning (apraxia) are severe in the early years of life and intensive evidence-based motor speech therapies should be applied [Morgan et al 2018]. Early phonologic awareness tasks should be implemented to support speech and later literacy development. Therapies addressing both receptive and expressive semantics and grammar are also recommended. The optimal intervention will be tailored to the child’s specific profile as it changes during development.
Social/Behavioral Concerns
Children may qualify for and benefit from interventions used in treatment of autism spectrum disorder, including applied behavior analysis (ABA). ABA therapy is targeted to the individual child's behavioral, social, and adaptive strengths and weaknesses and typically performed one on one with a board-certified behavior analyst.
Consultation with a developmental pediatrician may be helpful in guiding parents through appropriate behavior management strategies or providing prescription medications, such as medication used to treat attention-deficit/hyperactivity disorder (ADHD), when necessary.
Concerns about serious aggressive or destructive behavior can be addressed by a neurologist, developmental specialist, or psychiatrist.
Surveillance
Evaluation of Relatives at Risk
See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.
Therapies Under Investigation
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Genetic Counseling
Genetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. —ED.
Mode of Inheritance
SETBP1 haploinsufficiency disorder (SETBP1-HD) is an autosomal dominant disorder typically caused by a de novo pathogenic variant.
Risk to Family Members
Parents of a proband
- Most probands reported to date with SETBP1 haploinsufficiency disorder whose parents have undergone molecular genetic testing have the disorder as a result of a de novo SETBP1 pathogenic variant.
- Molecular genetic testing is recommended for the parents of the proband to confirm their genetic status and to allow reliable recurrence risk counseling.
- If the pathogenic variant identified in the proband is not identified in either parent and parental identity testing has confirmed biological maternity and paternity, the following possibilities should be considered:
- The proband has a de novo pathogenic variant.
- The proband inherited a pathogenic variant from a parent with germline (or somatic and germline) mosaicism. Note: Testing of parental leukocyte DNA is unlikely to detect somatic mosaicism and will not detect a pathogenic variant that is present in the germ cells only.
Sibs of a proband. The risk to the sibs of the proband depends on the genetic status of the proband's parents:
- If the SETBP1 pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, the recurrence risk to sibs is presumed to be low but is slightly greater than that of the general population because of the possibility of parental mosaicism; presumed parental mosaicism has been reported in one family with sib recurrence [Jansen et al 2021].
- If a parent of the proband is known to have the SETBP1 pathogenic variant identified in the proband, the risk to the sibs of inheriting the variant is 50%.
Offspring of a proband. Each child of an individual with SETBP1 haploinsufficiency disorder has a 50% chance of inheriting the SETBP1 pathogenic variant.
Other family members. Given that most probands with SETBP1 haploinsufficiency disorder reported to date have the disorder as a result of a de novo SETBP1 pathogenic variant, the risk to other family members is presumed to be low.
Related Genetic Counseling Issues
Family planning
- The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
- It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to parents of affected individuals and to young adults who are mildly affected.
Prenatal Testing and Preimplantation Genetic Testing
Once the SETBP1 pathogenic variant has been identified in an affected family member, prenatal and preimplantation genetic testing are possible.
Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful.
Resources
GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here.
- SETBP1 SocietyP.O. Box 301584Austin TX 78703Phone: 512-522-8072Email: info@setbp1.org
- American Association on Intellectual and Developmental Disabilities (AAIDD)Phone: 202-387-1968Fax: 202-387-2193
- Apraxia KidsPhone: 412-785-7072Email: info@apraxia-kids.org
- MedlinePlus
- VOR: Speaking out for people with intellectual and developmental disabilitiesPhone: 877-399-4867Email: info@vor.net
- Simons Searchlight RegistrySimons Searchlight aims to further the understanding of rare genetic neurodevelopmental disorders.Phone: 855-329-5638Fax: 570-214-7327Email: coordinator@simonssearchlight.org
Molecular Genetics
Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.
Molecular Pathogenesis
SETBP1 encodes SET-binding protein (SEB), which regulates transcription processes by binding to different promotor regions. Although SEB is highly expressed during brain development, its precise functions and molecular mechanisms in the brain and neuronal pathways are still largely unknown.
Mechanism of disease causation. Haploinsufficiency of the SET-binding protein
Cancer and Benign Tumors
Somatic gain-of-function SETBP1 pathogenic variants have been identified in several types of myelodysplastic/myeloproliferative neoplasms, including atypical chronic myeloid leukemia, chronic myelomonocytic leukemia, and juvenile myelomonocytic leukemia, as well as in secondary acute myeloid leukemia [Makishima 2017]. To date, these activating variants are limited to the cells in these neoplasms.
The SETBP1 pathogenic variants that cause SETBP1 haploinsufficiency disorder are germline loss-of-function variants present in every cell in the body of the affected individual. These loss-of-function variants are not associated with an increase in tumorigenesis.
Chapter Notes
Acknowledgments
The authors would like to thank all individuals with SETBP1 haploinsufficiency disorder and their families for sharing their medical and personal stories within the clinic, during scientific studies, and at (inter)national meetings. They are the true experts, and based upon their knowledge we have been able to write this GeneReview chapter.
Revision History
- 18 November 2021 (bp) Review posted live
- 13 July 2021 (bvb) Original submission
References
Published Guidelines / Consensus Statements
- National Institute for Health and Care Excellence. Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide. Available online. 2017. Accessed 9-12-22.
Literature Cited
- Braden RO, Boyce JO, Stutterd CA, Pope K, Goel H, Leventer RJ, Scheffer IE, Morgan AT. Speech, language, and oromotor skills in patients with polymicrogyria. Neurology. 2021;96:e1898-e1912. [PubMed: 33589534]
- Coe BP, Witherspoon K, Rosenfeld JA, van Bon BW, Vulto-van Silfhout AT, Bosco P, Friend KL, Baker C, Buono S, Vissers LE, Schuurs-Hoeijmakers JH, Hoischen A, Pfundt R, Krumm N, Carvill GL, Li D, Amaral D, Brown N, Lockhart PJ, Scheffer IE, Alberti A, Shaw M, Pettinato R, Tervo R, de Leeuw N, Reijnders MR, Torchia BS, Peeters H, O'Roak BJ, Fichera M, Hehir-Kwa JY, Shendure J, Mefford HC, Haan E, Gécz J, de Vries BB, Romano C, Eichler EE. Refining analytses of copy number variation identifies specific genes associated with developmental delay. Nat Genet. 2014;46:1063-71. [PMC free article: PMC4177294] [PubMed: 25217958]
- Dodd B, Ttoffari-Eecen T, Brommeyer K, Ng K, Reilly S, Morgan A. Delayed and disordered development of articulation and phonology between four and seven years. Child Lang Teach Ther. 2018;34:83-5.
- Foy JG, Mann VA. Speech production deficits in early readers: predictors of risk. Reading and Writing. 2012;25:799-830. [PMC free article: PMC3303057] [PubMed: 22448102]
- Jansen NA, Braden RO, Srivastava S, Otness EF, Lesca G, Rossi M, Nizon M, Bernier RA, Quelin C, van Haeringen A, Kleefstra T, Wong MM, Whalen S, Fisher SE, Morgan AT, van Bon BW. Clinical delineation of SETBP1 haploinsufficiency disorder. Eur J Hum Genet. 2021;29:1198-205. [PMC free article: PMC8385049] [PubMed: 33867525]
- Leonardi E, Bettella E, Pelizza MF, Aspromonte MC, Polli R, Boniver C, Sartori S, Milani D, Murgia A. Identification of SETBP1 mutations by gene panel sequencing in individuals with intellectual disability or with "developmental and epileptic encephalopathy." Front Neurol. 2020;11:593446. [PMC free article: PMC7772201] [PubMed: 33391157]
- Makishima H. Somatic SETBP1 mutations in myeloid neoplasms. Int J Hematol. 2017;105:732-42. [PubMed: 28447248]
- Morgan A, Braden R, Wong MM, Colin E, Amor D, Liegeois F, Srivastava S, Vogel A, Bizaoui V, Ranguin K, Fisher SE, van Bon BW. Speech and language deficits are central to SETBP1 haploinsufficiency disorder. Eur J Hum Genet. 2021;29:1216-25. [PMC free article: PMC8384874] [PubMed: 33907317]
- Morgan A, Dodrill P, Ward E. Interventions for oropharyngeal dysphaia in children with neurological impairment. Cochrane Database Syst Rev. 2012;10:CD009456. [PubMed: 23076958]
- Morgan A, Günther T. Clinical management of articulation impairment in children. In: Dodd B, Morgan A, eds. Intervention Case Studies of Child Speech Impairment. Chap 2. London: J&R Press; 2017.
- Morgan A, Murray E, Liegeois F. Interventions for childhood apraxia of speech. Cochrane Database Syst Rev. 2018;5:CD006278. [PMC free article: PMC6494637] [PubMed: 29845607]
- Reilly S, McKean C, Morgan A, Wake M. Identifying and managing common childhood language and speech impairments. BMJ. 2015;350:h2318. [PubMed: 25976972]
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-24. [PMC free article: PMC4544753] [PubMed: 25741868]
- Stenson PD, Mort M, Ball EV, Chapman M, Evans K, Azevedo L, Hayden M, Heywood S, Millar DS, Phillips AD, Cooper DN. The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting. Hum Genet. 2020;139:1197-207. [PMC free article: PMC7497289] [PubMed: 32596782]
Publication Details
Author Information and Affiliations
University of Melbourne
Royal Children’s Hospital
Melbourne, Australia
Boston Children’s Hospital
Boston, Massachusetts
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Nijmegen, the Netherlands
Publication History
Initial Posting: November 18, 2021.
Copyright
GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.
For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.
For questions regarding permissions or whether a specified use is allowed, contact: ude.wu@tssamda.
Publisher
University of Washington, Seattle, Seattle (WA)
NLM Citation
Morgan A, Srivastava S, Duis J, et al. SETBP1 Haploinsufficiency Disorder. 2021 Nov 18. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024.